The Lab On Chips Market, valued at US$ 8.0 Bn in 2022, is poised for substantial growth, with an estimated CAGR of 11.2% from 2023 to 2031, reaching US$ 20.7 Bn by the end of 2031. This comprehensive market research study delves into the dynamics driving this growth, the key players, competitive landscape, market drivers, challenges, and future outlook.
Download sample PDF copy of report: https://t.ly/nGhs_
Market Drivers:
The primary driver for the Lab on Chips market is the increasing prevalence of chronic diseases globally. Lab on chips, with their ability to provide accurate and rapid results, especially in diagnosing chronic disorders, are becoming indispensable in the healthcare sector. The rise in the geriatric population and lifestyle changes contribute to the surge in long-term disorders, necessitating accurate and cost-effective diagnostic services.
Personalized Medicine and Innovation:
The growing popularity of personalized medical devices, driven by heightened public awareness of health and illnesses, is another significant factor fueling market growth. Key industry players are investing heavily in RD to introduce innovative products, expanding their portfolio with novel microfluidic systems for diagnostics and healthcare services.
Market Segmentation:
The Lab on Chips market is segmented by product (instruments, reagents consumables, software services), application (genomics proteomics, diagnostics, drug discovery, others), and end-use industry (biotechnology pharmaceutical companies, hospitals, diagnostics centers, academic research institutes, others).
Key Players and Developments:
- Becton, Dickinson and Company
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific
- Hoffmann-La Roche AG
- Abbott Laboratories
- IDEX Corporation
- RainDance Technologies, Inc.
- Standard BioTools Inc.
